- Home
- UBS vs BMY Comparison
UBS vs BMY Comparison
Compare UBS & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UBS | BMY |
|---|---|---|
| Founded | 1862 | 1887 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.4B | 114.0B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | UBS | BMY |
|---|---|---|
| Price | $39.94 | $61.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 15 |
| Target Price | $60.30 | ★ $61.93 |
| AVG Volume (30 Days) | 2.6M | ★ 11.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 1.34% | ★ 4.04% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.10 | N/A |
| Revenue Next Year | $3.44 | N/A |
| P/E Ratio | ★ $17.22 | $17.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.75 | $42.52 |
| 52 Week High | $49.36 | $63.33 |
Technical Indicators
Market Signals| Indicator | UBS | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 29.15 | 62.12 |
| Support Level | $39.19 | $59.23 |
| Resistance Level | $42.57 | $62.05 |
| Average True Range (ATR) | 0.79 | 1.22 |
| MACD | -0.20 | -0.05 |
| Stochastic Oscillator | 25.22 | 61.81 |
Price Performance
Historical ComparisonAbout UBS UBS Group AG Registered
UBS is a global financial institution built around its core strength in wealth management, serving high and ultra-high-net-worth individuals. In Switzerland, it also operates as a traditional retail and commercial bank. Its investment bank and asset management divisions complement the wealth business, providing tailored solutions to UBS clients while serving third-party customers by leveraging UBS' global reach and expertise.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.